Navigation Links
EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
Date:2/7/2008

Application to be reviewed under European Accelerated Assessment Procedure

BOULDER, Colo., Feb. 7 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today announced that the European Medicines Agency (EMEA) has accepted for review the Company's Marketing Authorization Application (MAA) for Vidaza(R) (azacitidine for injection) in patients with higher-risk myelodysplastic syndromes (MDS) and announced its intent to review the application under the Accelerated Assessment Procedure. Pharmion submitted the Vidaza MAA to the EMEA earlier this month.

The Accelerated Assessment Procedure is granted for medicinal products that are expected to be of major public health interest, particularly from the point of view of therapeutic innovation. Accelerated Assessment reduces the time limit for the Committee for Medicinal Products for Human Use (CHMP) to give an opinion from 210 days to 150 days. At any time during the marketing authorization application evaluation, the CHMP may decide to continue the assessment under standard centralized procedure timelines.

The application is based upon clinical data which include the results from the Company's Phase 3 multi-center, international, randomized study of Vidaza(R) (azacitidine for injection) in the treatment of patients with higher-risk MDS. The primary objective of this Phase 3 trial was to demonstrate superiority in overall survival of Vidaza versus conventional care regimens, and these data were presented at the American Society of Hematology annual meeting in December 2007.

Vidaza has been designated as an Orphan Medicinal Product in the EU for the treatment of MDS, which, if approved, entitles the drug to ten years of market exclusivity for the approved indication
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Accepts Ranexa(R) sNDA and NDA for Filing
2. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
3. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
4. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
5. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
6. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
11. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 27, 2014 The “Molecular Diagnostic ... Microbiology), Technology (PCR, INAAT, DNA Sequencing), End User ... Software) - Global Forecast to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... and forecasts of the revenue and share analysis. ...
(Date:10/27/2014)... , Oct. 27, 2014 Pressure ... a worldwide leader in the development and sale ... life sciences research market, today announced that Professor ... a novel, accurate, highly reproducible, and robust method ... routine high-throughput protein analysis on small needle biopsy ...
(Date:10/26/2014)... (PRWEB) October 26, 2014 The report ... by Application - Global Trends & Forecast to 2019", ... analysis and forecasting of volume consumed and value generated. ... 4,253.9 KT in 2014 to 6,701.3 KT by 2019, ... , Browse 91 market data tables and 22 figures ...
(Date:10/25/2014)... According to new market research ... Types (Colocation, Enterprise, Telecom), by Design Types (Electrical, ... 2, Tier 3, Tier 4) - Global Forecast ... the Data Center Construction Market into various segments ... This research report also identifies the factors driving ...
Breaking Biology Technology:Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 2Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 3Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 4Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4
... (Nasdaq: PRXL ) will release Third Quarter Fiscal ... the close of the stock,market. The announcement will be ... the PR Newswire website at http://www.prnewswire.com ., ... webcast at 10:00 a.m. EDT,on Thursday, April 24, 2008 ...
... N.C., March 26 Campbell Alliance, the leading,management ... announced today that George Schmidt, Vice President,in the ... the EyeForPharma,Sales Force Effectiveness (SFE) conference. The event ... the Centre Convencions Internacional in Barcelona, Spain., ...
... March 26 /Xinhua-PRNewswire-FirstCall/,-- Kiwa Bio-Tech Products Group Corporation ... year ended December 31, 2007 were,$9,129,779 an increase ... sales from continuing operations were $9,129,779 and $2,506,715 ... 2006, respectively,representing an increase of $6,623,064 or 264.2%. ...
Cached Biology Technology:PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call 2Campbell Alliance Sales Practice to Conduct Workshop at EyeForPharma SFE Europe Conference 2Campbell Alliance Sales Practice to Conduct Workshop at EyeForPharma SFE Europe Conference 3Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 2Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 3Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 4Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 5Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 6Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 7
(Date:10/30/2014)... have developed a suite of technologies that can be ... has applications in everything from search and rescue to ... a platform for computer-mediated communication between humans and dogs ... dogs, behavioral signals and sending them clear and unambiguous ... professor of computer science at NC State and co-lead ...
(Date:10/30/2014)... 29, 2014  Securus Technologies, a leading ... solutions for public safety, investigation, corrections and ... exciting enhancements to its THREADS™ product, which ... actionable intelligence and focused leads for investigators. ... technological innovation through identifying and delivering solutions ...
(Date:10/29/2014)... lose their hair as a consequence of chemotherapy will ... the scalp cooling technology that prevents hair loss. , ... pioneered by global scalp cooling manufacturing company, Paxman Coolers, ... department of the University of Huddersfield. , The research ... has a background in the pharmacology of cancer treatment, ...
Breaking Biology News(10 mins):New tech aims to improve communication between dogs and humans 2Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2
... common form of brewer's yeast, University of Wisconsin-Madison researchers have ... to act as a master regulatory switch -- a control ... may contribute to serious neurological disorders. , The work, published ... shows how a mutation in a single gene can have ...
... to determine the sequence of nucleotide bases in the ... at UC San Diego and eight other universities and ... lower the cost to only $1,000 per human genome ... crucial to understanding and routinely treating hundreds of inherited ...
... have shown that some simple biodegradable liquids can stop ... could significantly impact medicine. , When the liquid, composed ... wounds, the peptides self-assemble into a nanoscale protective barrier ... the injury heals, the nontoxic gel is broken down ...
Cached Biology News:From a lowly yeast, researchers divine a clue to human disease 2Scientists win grants to develop $1,000 genome sequencing technology 2MIT material stops bleeding in seconds 2MIT material stops bleeding in seconds 3